<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742625</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00443</org_study_id>
    <secondary_id>NCI-2009-00443</secondary_id>
    <secondary_id>CDR0000612758</secondary_id>
    <secondary_id>CALGB 10502</secondary_id>
    <secondary_id>CALGB-10502</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>P30CA014236</secondary_id>
    <nct_id>NCT00742625</nct_id>
    <nct_alias>NCT01647061</nct_alias>
  </id_info>
  <brief_title>Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <official_title>Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and best dose of bortezomib when given together
      with daunorubicin and cytarabine and to see how well it works in treating older patients with
      previously untreated acute myeloid leukemia. Bortezomib may stop the growth of cancer cells
      by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
      daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells,
      either by killing the cells or by stopping them from dividing. Giving bortezomib together
      with combination chemotherapy may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the remission induction response rate (complete response [CR] and CR with
      incomplete platelet recovery [CRp]) in older patients with previously untreated acute myeloid
      leukemia treated with induction therapy comprising bortezomib in combination with
      daunorubicin hydrochloride and cytarabine.

      II. To define the maximum tolerated dose of bortezomib when administered in combination with
      intermediate-dose cytarabine after induction therapy.

      SECONDARY OBJECTIVES:

      I. To describe the disease-free survival of patients treated with this regimen. II. To
      describe the overall survival of patients treated with this regimen. III. To evaluate the
      treatment-related toxicities in these patients.

      OUTLINE: This is a multicenter, dose-escalation study of bortezomib. Doses of bortezomib are
      escalated during remission consolidation therapy.

      REMISSION INDUCTION THERAPY: Remission induction course 1: Patients receive bortezomib IV
      over 3-5 seconds on days 1, 4, 8, and 11; daunorubicin hydrochloride IV on days 1-3; and
      cytarabine IV continuously over 168 hours on days 1-7.

      After completion of remission induction course 1, patients undergo bone marrow aspiration and
      biopsy for evaluation of response. Patients achieving a complete response (CR) or partial
      response (PR) proceed to remission consolidation therapy. Patients achieving a CR with
      incomplete platelet recovery (CRp) proceed to remission consolidation therapy after platelet
      counts recover. Patients with persistent leukemia (&gt;= 20% bone marrow cellularity and &gt;= 5%
      bone marrow myeloblasts) proceed to remission induction course 2.

      REMISSION INDUCTION COURSE 2: Patients receive bortezomib IV over 3-5 seconds on days 1 and
      4; daunorubicin hydrochloride IV on days 1 and 2; and cytarabine IV continuously over 120
      hours on days 1-5.

      After completion of remission induction course 2, patients undergo bone marrow aspiration and
      biopsy for evaluation of response. Patients achieving a CR or PR proceed to remission
      consolidation therapy. Patients achieving a CRp proceed to remission consolidation therapy
      after platelet counts recover. Patients with residual leukemia who do not meet the criteria
      for PR are removed from the study.

      REMISSION CONSOLIDATION THERAPY: Patients receive bortezomib IV over 3-5 seconds on days 1,
      4, 8, and 11 and intermediate-dose cytarabine IV over 3 hours on days 1-5. Patients then
      undergo bone marrow aspiration and biopsy for evaluation of response. Patients achieving a CR
      or who demonstrate continuing CR receive a second course of remission consolidation therapy
      beginning 2-4 weeks after blood counts recover.

      After completion of study therapy, patients are followed every 2 months for 2 years, every 3
      months for 2 years, and then annually for up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Induction Response</measure>
    <time_frame>2 months</time_frame>
    <description>Response was calculated according to Revised International Working Group (IWG) criteria for Acute myeloid leukemia (AML)
A response was defined as the portion of participants who achieved a complete response (CR) or CR with incomplete platelet recovery(CRp) during induction.
A CR is defined as those with &gt; 20% cellularity of bone marrow biopsy, no presence of extramedullary leukemia for AML, &lt;5 % myeloblast cells for bone marrow with peripheral blood and normal complete blood count (absolute neutrophils &gt; 1000 mL and platelets &gt;= 100,000 mL).
A CRp is defined as a CR except platelets &lt; 100,000 mL without need for transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine</measure>
    <time_frame>during consolidation cycle 1 (42 days)</time_frame>
    <description>DLTs were considered only during the first cycle of consolidation therapy and included grade 3 or 4 sensory or autonomic neuropathy, persistent grade 4 thrombocytopenia or neutropenia at day 42 in the absence of AML,any grade 4 or 5 nonhematologic toxicity, and any grade 3 nonhematologic toxicity (excluding neuropathy and toxicities secondary to neutropenia and sepsis) that did not resolve to grade 2 by day 42 unless attributable to persistent or recurrent AML. Grade 4 anorexia (requiring total parenteral nutrition) and grade 4 fatigue (requiring bed rest) were not considered DLTs.
Toxicity was graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grading scale is as follows: grade 1: mild; grade 2: moderate; grade 3: Severe; grade 4: Life Threatening; grade 5: Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Duration of study (up to 10 years)</time_frame>
    <description>Disease-free survival (DFS) was measured as the interval from achievement of CR until relapse or death, regardless of cause. DFS was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Duration of study (up to 10 years)</time_frame>
    <description>Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (daunorubicin hydrochloride and bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (daunorubicin hydrochloride and bortezomib)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>daunomycin hydrochloride</other_name>
    <other_name>daunorubicin</other_name>
    <other_name>RP-13057</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (daunorubicin hydrochloride and bortezomib)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (daunorubicin hydrochloride and bortezomib)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unequivocally histologically confirmed acute myeloid leukemia (AML)

          -  At least 20% blasts in the bone marrow based on WHO criteria

          -  No acute promyelocytic leukemia (M3)

          -  Antecedent hematologic disorder or myelodysplastic syndromes allowed provided the
             patient did not receive cytotoxic chemotherapy, including azacitidine and decitabine,
             for their pre-leukemic disorder

          -  Concurrent enrollment on CALGB-8461 required

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No ataxia, cranial neuropathy, or peripheral neuropathy &gt;= grade 2

          -  LVEF &gt;= 40% by ECHO or MUGA scan

          -  No signs or symptoms of congestive heart failure

          -  DLCO &gt;= 50% (corrected for hemoglobin)

          -  No prior therapy for leukemia or pre-leukemic disorders, except for the following:

               -  emergency leukapheresis;

               -  emergency treatment for hyperleukocytosis with hydroxyurea;

               -  cranial radiotherapy for CNS leukostasis (one dose only);

               -  growth factor/cytokine support

          -  No other concurrent chemotherapy, except for the following:

               -  I) steroids administered for adrenal failure, hypersensitivity reactions, or
                  septic shock;

               -  II) hormones administered for non-disease-related conditions (e.g., insulin for
                  diabetes or estrogens or progestins for gynecologic indications)

          -  No concurrent palliative radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eyal Attar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System CCOP</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System/Center for Advanced Medicine</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists PA</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <results_first_submitted>January 2, 2013</results_first_submitted>
  <results_first_submitted_qc>January 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2013</results_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 2008 and February 2010, 98 participants were recruited at 15 CALGB member institutions and their affiliated hospitals.</recruitment_details>
      <pre_assignment_details>Three (3) participants did not begin treatment and were excluded from all analyses per study design</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib + Daunorubicin + Cytarabine</title>
          <description>Bortezomib:
Induction: 1.3 mg/sq m IV infusion Days 1,4,8,11 (Days 1, 4 only if 2nd induction)
Consolidation: 0.7 OR 1 OR 1.3 mg/sq m IV infusion Days 1,4,8,11
Cytarabine:
Induction: 100 mg/sq m/day CIVI Days 1-7 (Days 1-5 only if 2nd induction) Consolidation: 2 g/sq m/day IV infusion Days 1-5
Daunorubicin Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Remission Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed induction</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non protocol treatment</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Consolidation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib + Daunorubicin + Cytarabine</title>
          <description>Bortezomib:
Induction: 1.3 mg/sq m IV infusion Days 1,4,8,11 (Days 1, 4 only if 2nd induction)
Consolidation: 0.7 OR 1 OR 1.3 mg/sq m IV infusion Days 1,4,8,11
Cytarabine:
Induction: 100 mg/sq m/day CIVI Days 1-7 (Days 1-5 only if 2nd induction) Consolidation: 2 g/sq m/day IV infusion Days 1-5
Daunorubicin Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="60" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>Classifies patients according to their functional impairment. Scores range from 0 (fully active) to 5 (death).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 - Fully Active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - Ambulatory, restricted strenuous activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Ambulatory, unable to perform work activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Induction Response</title>
        <description>Response was calculated according to Revised International Working Group (IWG) criteria for Acute myeloid leukemia (AML)
A response was defined as the portion of participants who achieved a complete response (CR) or CR with incomplete platelet recovery(CRp) during induction.
A CR is defined as those with &gt; 20% cellularity of bone marrow biopsy, no presence of extramedullary leukemia for AML, &lt;5 % myeloblast cells for bone marrow with peripheral blood and normal complete blood count (absolute neutrophils &gt; 1000 mL and platelets &gt;= 100,000 mL).
A CRp is defined as a CR except platelets &lt; 100,000 mL without need for transfusion.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Daunorubicin + Cytarabine</title>
            <description>Bortezomib:
Induction: 1.3 mg/sq m IV infusion Days 1,4,8,11 (Days 1, 4 only if 2nd induction)
Consolidation: 0.7 OR 1 OR 1.3 mg/sq m IV infusion Days 1,4,8,11
Cytarabine:
Induction: 100 mg/sq m/day CIVI Days 1-7 (Days 1-5 only if 2nd induction) Consolidation: 2 g/sq m/day IV infusion Days 1-5
Daunorubicin Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Induction Response</title>
          <description>Response was calculated according to Revised International Working Group (IWG) criteria for Acute myeloid leukemia (AML)
A response was defined as the portion of participants who achieved a complete response (CR) or CR with incomplete platelet recovery(CRp) during induction.
A CR is defined as those with &gt; 20% cellularity of bone marrow biopsy, no presence of extramedullary leukemia for AML, &lt;5 % myeloblast cells for bone marrow with peripheral blood and normal complete blood count (absolute neutrophils &gt; 1000 mL and platelets &gt;= 100,000 mL).
A CRp is defined as a CR except platelets &lt; 100,000 mL without need for transfusion.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete response with incomplete platelet recover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine</title>
        <description>DLTs were considered only during the first cycle of consolidation therapy and included grade 3 or 4 sensory or autonomic neuropathy, persistent grade 4 thrombocytopenia or neutropenia at day 42 in the absence of AML,any grade 4 or 5 nonhematologic toxicity, and any grade 3 nonhematologic toxicity (excluding neuropathy and toxicities secondary to neutropenia and sepsis) that did not resolve to grade 2 by day 42 unless attributable to persistent or recurrent AML. Grade 4 anorexia (requiring total parenteral nutrition) and grade 4 fatigue (requiring bed rest) were not considered DLTs.
Toxicity was graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grading scale is as follows: grade 1: mild; grade 2: moderate; grade 3: Severe; grade 4: Life Threatening; grade 5: Death.</description>
        <time_frame>during consolidation cycle 1 (42 days)</time_frame>
        <population>Participants who were registered to bortezomib consolidation were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib (0.7 mg/m^2) + Int-DAC</title>
            <description>Bortezomib (0.7 mg/m^2) + Intermediate Dose Cytarabine (Int-DAC)</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib (1.0 mg/m^2) + Int-DAC</title>
            <description>Bortezomib (1.0 mg/m^2) + Intermediate Dose Cytarabine (Int-DAC)</description>
          </group>
          <group group_id="O3">
            <title>Bortezomib (1.3 mg/m^2) + Int-DAC</title>
            <description>Bortezomib (1.3 mg/m^2) + Intermediate Dose Cytarabine (Int-DAC)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine</title>
          <description>DLTs were considered only during the first cycle of consolidation therapy and included grade 3 or 4 sensory or autonomic neuropathy, persistent grade 4 thrombocytopenia or neutropenia at day 42 in the absence of AML,any grade 4 or 5 nonhematologic toxicity, and any grade 3 nonhematologic toxicity (excluding neuropathy and toxicities secondary to neutropenia and sepsis) that did not resolve to grade 2 by day 42 unless attributable to persistent or recurrent AML. Grade 4 anorexia (requiring total parenteral nutrition) and grade 4 fatigue (requiring bed rest) were not considered DLTs.
Toxicity was graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grading scale is as follows: grade 1: mild; grade 2: moderate; grade 3: Severe; grade 4: Life Threatening; grade 5: Death.</description>
          <population>Participants who were registered to bortezomib consolidation were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival (DFS) was measured as the interval from achievement of CR until relapse or death, regardless of cause. DFS was estimated using the Kaplan Meier method.</description>
        <time_frame>Duration of study (up to 10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Daunorubicin + Cytarabine</title>
            <description>Bortezomib:
Induction: 1.3 mg/sq m IV infusion Days 1,4,8,11 (Days 1, 4 only if 2nd induction)
Consolidation: 0.7 OR 1 OR 1.3 mg/sq m IV infusion Days 1,4,8,11
Cytarabine:
Induction: 100 mg/sq m/day CIVI Days 1-7 (Days 1-5 only if 2nd induction) Consolidation: 2 g/sq m/day IV infusion Days 1-5
Daunorubicin Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free survival (DFS) was measured as the interval from achievement of CR until relapse or death, regardless of cause. DFS was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method.</description>
        <time_frame>Duration of study (up to 10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Daunorubicin + Cytarabine</title>
            <description>Bortezomib:
Induction: 1.3 mg/sq m IV infusion Days 1,4,8,11 (Days 1, 4 only if 2nd induction)
Consolidation: 0.7 OR 1 OR 1.3 mg/sq m IV infusion Days 1,4,8,11
Cytarabine:
Induction: 100 mg/sq m/day CIVI Days 1-7 (Days 1-5 only if 2nd induction) Consolidation: 2 g/sq m/day IV infusion Days 1-5
Daunorubicin Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib + Daunorubicin + Cytarabine</title>
          <description>Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="51" subjects_affected="43" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other (Specify __)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest cause unknown (non-fatal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Thyroid function high (hyperthyroidism thyrotoxicosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Enteritis (inflammation of the small bowel)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ileus GI (functional obstruction of bowel i.e. neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ulcer GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Edema:head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="56" subjects_affected="29" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify __)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DL(co))</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="51" subjects_affected="43" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Alkalosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Calcium serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Glucose serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Glucose serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Magnesium serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Magnesium serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Phosphate serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Potassium serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Potassium serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sodium serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sodium serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Uric acid serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing nasal stuffiness postnasal drip)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Edema larynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify __)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Phlebitis (including superficial thrombosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia (non-myocardial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe</sub_title>
                <counts group_id="E1" events="67" subjects_affected="50" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="146" subjects_affected="76" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other (Specify __)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="86" subjects_affected="63" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fistula, GI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="95" subjects_affected="61" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ulcer GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ulcer, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="49" subjects_affected="38" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Allergy/Immunology - Other (Specify __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="73" subjects_affected="46" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify __)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="65" subjects_affected="40" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="73" subjects_affected="49" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DL(co))</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="39" subjects_affected="23" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuroendocrine: ADH secretion abnormality (e.g. SIADH or low ADH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="142" subjects_affected="76" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="144" subjects_affected="75" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Alkalosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Calcium serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Calcium serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Glucose serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="39" subjects_affected="23" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Glucose serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Magnesium serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Magnesium serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Phosphate serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Potassium serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Potassium serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sodium serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sodium serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Uric acid serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Myositis (inflammation/damage of muscle)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="36" subjects_affected="21" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="70" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Obstruction, GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing nasal stuffiness postnasal drip)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hiccoughs (hiccups singultus)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify __)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify __)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="68" subjects_affected="53" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Urticaria (hives welts wheals)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vascular - Other (Specify __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eyal Attar, MD</name_or_title>
      <organization>Massachusetts General Hospital Cancer Center</organization>
      <phone>617-724-1124</phone>
      <email>eattar@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

